ABSTRACT BACKGROUND: Multiple phase-2 trials in men with biochemically-recurrent prostate cancer (BRPC) have assessed the impact of nonhormonal agents on PSA kinetics. We have previously

demonstrated that changes in PSA kinetics correlate with metastasis-free survival; however, it is unknown whether these changes also correlate with overall survival (OS). METHODS: We

performed a combined retrospective analysis of 146 men with BRPC treated on phase-2 trials using one of four investigational drugs: lenalidomide (_n_=60), marimastat (_n_=39), ATN-224

(_n_=22) and imatinib (_n_=25). We examined factors influencing OS, including within-subject changes in PSA kinetics (PSA slope, PSA doubling time and PSA velocity), before and 6 months

androgen-deprivation therapy prior to metastases), baseline PSA velocity and increase in PSA velocity on therapy remained independent predictors of OS. Median OS for men with an increase in

PSA velocity on treatment was 115.4 months and was not reached for men with a decrease in PSA velocity (hazard ratio=0.47, 95% confidence interval 0.25–0.88; _P_=0.02). CONCLUSIONS: This

hypothesis-generating study suggests that within-subject changes in PSA velocity after initiation of nonhormonal therapy may correlate with OS in men with BRPC. If validated in prospective

trials, change in PSA velocity may represent a reasonable intermediate end point for screening new agents in these patients. Access through your institution Buy or subscribe This is a

preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 4 print issues and online access $259.00 per

year only $64.75 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS EARLY PSA

DECLINE AFTER STARTING SECOND-GENERATION HORMONE THERAPY IN THE POST-DOCETAXEL SETTING PREDICTS CANCER-SPECIFIC SURVIVAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER Article 07 November

2023 REAL-WORLD OUTCOMES FOLLOWING BIOCHEMICAL RECURRENCE AFTER DEFINITIVE THERAPY WITH A SHORT PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME: POTENTIAL ROLE OF EARLY SECONDARY TREATMENT Article

Open access 13 September 2024 IS TIME TO CASTRATION RESISTANT PROSTATE CANCER A POTENTIAL INTERMEDIATE END-POINT FOR TIME TO METASTASIS AMONG MEN INITIATING ANDROGEN DEPRIVATION THERAPY FOR

NON-METASTATIC PROSTATE CANCER WITH RAPID PSA DOUBLING TIME (<9 MONTHS)? Article 01 September 2022 REFERENCES * Paller CJ, Antonarakis ES . Management of biochemically recurrent prostate

cancer after local therapy: evolving standards of care and new directions. _Clin Adv Hematol Oncol_ 2013; 11: 14. PubMed  PubMed Central  Google Scholar  * Boccon‐Gibod L, Djavan B, Hammerer

P, Hoeltl W, Kattan M, Prayer‐Galetti T _et al_. Management of prostate‐specific antigen relapse in prostate cancer: a European consensus. _Int J Clin Pract_ 2004; 58: 382–390. Article 

PubMed  Google Scholar  * Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T _et al_. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer

after radical prostatectomy. _J Urol_ 2004; 171: 1141–1147. Article  PubMed  Google Scholar  * Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E _et al_. Rosiglitazone versus

placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapy. _Cancer_ 2004; 101: 1569–1574. Article  CAS 

PubMed  Google Scholar  * Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M _et al_. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a

prospective randomized, double-blind, phase I/II trial. _Clin Cancer Res_ 2005; 11: 4437–4443. Article  CAS  PubMed  Google Scholar  * Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi

V, Pili R _et al_. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or

radiotherapy. _Urology_ 2007; 69: 526–531. Article  PubMed  Google Scholar  * Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW . Celecoxib versus placebo for men with prostate

cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. _J Clin Oncol_ 2006; 24: 2723–2728. Article  CAS  PubMed  Google Scholar  * Lin J,

Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P _et al_. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with

biochemically recurrent hormone-naive prostate cancer. _Urol Oncol_ 2013; 31: 581–588. Article  CAS  PubMed  Google Scholar  * Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J _et

al_. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. _J Urol_ 2008; 180:

2011–2018. Article  CAS  PubMed  Google Scholar  * McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ _et al_. Safety and immunological efficacy of a DNA vaccine encoding

prostatic acid phosphatase in patients with stage D0 prostate cancer. _J Clin Oncol_ 2009; 27: 4047–4054. Article  CAS  PubMed  PubMed Central  Google Scholar  * Schweizer M, Zhou X, Wang H,

Yang T, Shaukat F, Partin A _et al_. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation

therapy. _Ann Oncol_ 2013; 24: 2881–2886. Article  CAS  PubMed  PubMed Central  Google Scholar  * Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN _et al_. Evaluation of

prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. _J Natl Cancer Inst_ 2006; 98: 516–521. Article  PubMed  Google Scholar  * Hussain M, Tangen CM, Higano C,

Schelhammer PF, Faulkner J, Crawford ED _et al_. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate

cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). _J Clin Oncol_ 2006; 24: 3984–3990. Article  PubMed  Google Scholar  * Keizman D, Zahurak M, Sinibaldi V, Carducci M,

Denmeade S, Drake C _et al_. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. _Clin Cancer Res_ 2010; 16:

5269–5276. Article  CAS  PubMed  PubMed Central  Google Scholar  * Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA . Changes in PSA kinetics predict metastasis‐free

survival in men with PSA‐recurrent prostate cancer treated with nonhormonal agents. _Cancer_ 2012; 118: 1533–1542. Article  CAS  PubMed  PubMed Central  Google Scholar  * Pound CR, Partin

AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC . Natural history of progression after PSA elevation following radical prostatectomy. _JAMA_ 1999; 281: 1591–1597. Article  CAS  Google

Scholar  * D'Amico AV, Chen M, Roehl KA, Catalona WJ, Preoperative PSA . velocity and the risk of death from prostate cancer after radical prostatectomy. _N Engl J Med_ 2004; 351:

125–135. Article  CAS  PubMed  Google Scholar  * Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. _J Am Statist Assoc_ 1958; 53: 457–481. Article  Google Scholar 

* Brookmeyer R, Crowley J . A confidence interval for the median survival time. _Biometrics_ 1982; 38: 29–41. Article  Google Scholar  * Antonarakis ES, Feng Z, Trock BJ, Humphreys EB,

Carducci MA, Partin AW _et al_. The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up. _BJU Int_

2012; 109: 32–39. Article  CAS  PubMed  Google Scholar  * Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA _et al_. Long‐term overall survival and

metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. _BJU

Int_ 2011; 108: 378–385. Article  PubMed  Google Scholar  * D’Amico AV, Renshaw AA, Sussman B, Chen M . Pretreatment PSA velocity and risk of death from prostate cancer following external

beam radiation therapy. _JAMA_ 2005; 294: 440–447. Article  PubMed  Google Scholar  * King CR, Presti JC, Brooks JD, Gill H, Spiotto MT . Postoperative prostate-specific antigen velocity

independently predicts for failure of salvage radiotherapy after prostatectomy. _IntJ Radiat Oncol Biol Phys_ 2008; 70: 1472–1477. Article  Google Scholar  * Armstrong AJ, Garrett-Mayer E,

Yang YO, Carducci MA, Tannock I, de Wit R _et al_. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. _J Clin Oncol_ 2007; 25: 3965–3970.

Article  PubMed  Google Scholar  * Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin C _et al_. Prostate-specific antigen changes as surrogate for overall survival in men with

metastatic castration-resistant prostate cancer treated with second-line chemotherapy. _J Clin Oncol_ 2013; 31: 3944–3950. Article  CAS  PubMed  PubMed Central  Google Scholar  * Paller C,

Olatoye D, Xie S, Zhou X, Denmeade S, Eisenberger M _et al_. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent

prostate cancer. _Prostate Cancer Prostatic Dis_ 2013; 17: 28–33. Article  PubMed  PubMed Central  Google Scholar  Download references ACKNOWLEDGEMENTS This work was partially supported by

NIH grants P30 CA006973 (ESA) and T32CA009071 (DLS). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA D L Suzman, 

X C Zhou, M L Zahurak & E S Antonarakis * Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, PA, USA J Lin Authors * D L Suzman View author publications You can

also search for this author inPubMed Google Scholar * X C Zhou View author publications You can also search for this author inPubMed Google Scholar * M L Zahurak View author publications You

can also search for this author inPubMed Google Scholar * J Lin View author publications You can also search for this author inPubMed Google Scholar * E S Antonarakis View author

publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to E S Antonarakis. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare

no conflict of interest. ADDITIONAL INFORMATION Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website SUPPLEMENTARY INFORMATION SUPPLEMENTARY

TABLES (DOC 251 KB) RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Suzman, D., Zhou, X., Zahurak, M. _et al._ Change in PSA velocity is a predictor of

overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials. _Prostate Cancer Prostatic Dis_ 18, 49–55

(2015). https://doi.org/10.1038/pcan.2014.44 Download citation * Received: 26 June 2014 * Revised: 28 August 2014 * Accepted: 23 September 2014 * Published: 11 November 2014 * Issue Date:

March 2015 * DOI: https://doi.org/10.1038/pcan.2014.44 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable

link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative